Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49 pembrolizumab plus chemotherapy in PD-L1-positive HR+/HER2- advanced breast cancer
NL-OMON59977Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Nov 2021; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59977.